WCLC 2025 - Posters & ePosters-P2.06.100 Initial Biomarker Results From the Phase 2A Study of AFM24 With Atezolizumab in Patients With Advanced/Metastatic NSCLC

P2.06.100 Initial Biomarker Results From the Phase 2A Study of AFM24 With Atezolizumab in Patients With Advanced/Metastatic NSCLC

Asset Subtitle

Hye Ryun Kim

Meta Tag

Speaker Hye Ryun Kim

Topic Pathology and Biomarkers